Blue Charm

Who owns Blue Charm?

Blue Charm is currently owned by Crédit Mutuel Equity through Crédit Mutuel Equity (1992 vintage), since 2025.

Hand-verified · updated 2026-05-07

About Blue Charm

Blue Charm, formally Blue Charm Adherence Inc., is a Canadian digital health company whose platform links real-world prescription behavior with patient experience data to improve medication adherence for the pharmaceutical and life sciences sectors. It operates a two-sided model in which patients access financial assistance, savings and engagement programs at the point of care, while life sciences partners receive real-world data, patient-reported outcomes and behavioral analytics through customized dashboards. Its product line spans a patient engagement platform, the ONE by Blue Charm financial assistance solution and real-world data services, deployed with disease associations, patient advocacy groups and clinics. The company markets national reach across Canada and positions itself in the patient-support and real-world-evidence segment of health technology.

Ownership journey

Blue Charm was founded in 2018 in Halifax, Nova Scotia, and built out its technology platform over 2020 and 2021, a period during which it also acquired Symbi Medical, before launching its patient engagement and ONE financial assistance programs from 2022. In September 2025 the company closed a USD 4 million seed round backed by Credit Mutuel Equity, the direct investment arm of the Credit Mutuel group, which invests from its own balance sheet and extends its activity into Canada alongside France, Germany, Switzerland and Belgium. Credit Mutuel Equity came in as a new minority investor supporting the company's growth, joining alongside a regional co-investor and existing early-stage backers who followed on. Credit Mutuel Equity remains an active shareholder and no exit or secondary transaction has been recorded.

Under PE ownership

The 2025 seed capital was earmarked for platform development, user acquisition and the expansion of solutions for pharmaceutical partners, per the company's funding disclosures. Led by chief executive Dr. Greg Patey, Blue Charm has widened its offering from early adherence tools into a broader real-world-data and patient-support suite covering engagement, financial assistance and outcomes collection across multiple therapeutic areas. The company reports strong platform engagement, citing an 80 percent re-engagement rate and engagement several times higher than typical consumer health apps. Following the investment it has begun clinic integration initiatives in 2026 to embed its programs deeper into the care pathway.